2022
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.Peer-Reviewed Original ResearchConceptsPD-L1 positivityPD-L1 protein expressionPD-L1 expressionGrade 3 cancersPD-L1TIL scoreTumor gradeMultivariate analysisHigher PD-L1 positivityTumor-infiltrating lymphocyte countsConclusionPD-L1 expressionProtein expressionPD-L1 immunohistochemistryChi-square testResultsPD-L1T1 cancersLymphocyte countT3 tumorsIndependent predictorsTumor sizeLarge tumorsPositivity rateCell positivityBreast cancerGrade 2
2015
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, DiGiovanna MP, Sanft TB, Pusztai L, Gross CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 2015, 121: 2544-2552. PMID: 25902916, DOI: 10.1002/cncr.29348.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyNAC useBreast cancerStage INational Cancer Data BaseStage III breast cancerStage IIIC cancerStage II diseaseStage III diseaseAdvanced breast cancerStandard of careLow-stage cancersLogistic regression analysisChi-square testIIIC cancersStage IIIAStage IIIBAdvanced cancerAfrican American individualsStage cancerPatterns of usePatientsAcademic centersClinical advantagesMultivariate analysis